TABLE 2.
Univariate Cox regression for clinicopathological and immune‐related variables
| Variable | Univariate | ||
|---|---|---|---|
| HR | 95% CI | P | |
| Age at surgery | 1.03 | 1.01‐1.05 | <.001* |
| Sex | |||
| Female | .76 | .52‐1.09 | .137 |
| Male | 1.00 | ||
| Adjuvant chemotherapy | |||
| Yes | .51 | .35‐.77 | .001* |
| No | 1.00 | ||
| Site | .382 | ||
| Unknown | .31 | .04‐2.25 | .248 |
| Distal | .85 | .59‐1.22 | .378 |
| Proximal | 1.00 | ||
| T Stage | .212 | ||
| Unknown | .48 | .12‐1.99 | .313 |
| T1 | .33 | .05‐2.37 | .267 |
| T2 | .51 | .25‐1.05 | .068 |
| T3 | .71 | .48‐1.05 | .088 |
| T4 | 1.00 | ||
| N Stage | |||
| N1 | .62 | .43‐.91 | .013* |
| N2 | 1.00 | ||
| Number of metastatic nodes | 1.04 | 1.01‐1.07 | .009* |
| Lymphovascular Invasion | .350 | ||
| Not Reported | .78 | .25‐2.50 | .677 |
| Present | 1.28 | .88‐1.84 | .193 |
| Absent | 1.00 | ||
| Extramural venous invasion | .002* | ||
| Not reported | .82 | .33‐2.03 | .665 |
| Present | 1.94 | 1.32‐2.85 | <.001* |
| Absent | 1.00 | ||
| Perineural invasion | .276 | ||
| Not reported | .62 | .20‐1.94 | .408 |
| Present | 1.36 | .86‐2.14 | .193 |
| Absent | 1.00 | ||
| Grade | <.001* | ||
| Not reported | .63 | .35‐1.15 | .133 |
| Low/moderate grade | .39 | .25‐.62 | <.001* |
| High Grade | 1.00 | ||
| CD8+ cell density ‐ Leading Edge (high vs low) | |||
| Tumor | .52 | .33‐.83 | .007* |
| Stroma | .69 | .43‐1.09 | .114 |
| CD11c+ cell density ‐ Leading Edge (high vs low) | |||
| Tumor | .80 | .51‐1.27 | .343 |
| Stroma | .52 | .33‐.83 | .006* |
| CD11c+PD‐L1+ cell density ‐ Leading Edge (high vs low) | |||
| Tumor | .57 | .35‐.92 | .021* |
| Stroma | .48 | .30‐.77 | .003* |
| CD11c+PD‐L1‐ cell density ‐ Leading Edge (high vs low) | |||
| Tumor | .88 | .56‐1.40 | .595 |
| Stroma | .84 | .53‐1.32 | .438 |
*
Significant values.